Research programme: anti-cancer therapeutics - Ascentage Pharma

Drug Profile

Research programme: anti-cancer therapeutics - Ascentage Pharma

Alternative Names: APG 2449; APG 2575; APG-1022; APG-1252

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Ascentage Pharma
  • Class Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Apoptosis stimulants; Proto oncogene protein c akt modulators; Proto oncogene protein c met inhibitors; Proto oncogene protein c-akt inhibitors; Proto-oncogene protein c mdm2 inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 10 Jan 2017 Research programme: anti-cancer therapeutics - Ascentage Pharma is available for licensing as of 10 Jan 2017. http://www.ascentagepharma.com/
  • 01 Nov 2016 Preclinical trials in Small cell lung cancer (Late-stage disease, Metastatic disease) in Australia (IV) (ACTRN12616001597482p) before November 2016
  • 01 Nov 2016 Preclinical trials in Solid tumours (Late-stage disease, Metastatic disease) in Australia (IV) (ACTRN12616001597482p) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top